Premium
Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease
Author(s) -
Noble Wendy,
Garwood Claire,
Stephenson John,
Kinsey Anna M.,
Hanger Diane P.,
Anderton Brian H.
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.08-113795
Subject(s) - minocycline , tangle , tau protein , neuroprotection , in vivo , amyloid beta , chemistry , alzheimer's disease , caspase , neuroscience , genetically modified mouse , biochemistry of alzheimer's disease , microglia , doxycycline , amyloid precursor protein , peptide , transgene , pathology , biology , apoptosis , programmed cell death , biochemistry , medicine , immunology , disease , inflammation , mathematics , antibiotics , pure mathematics , gene , microbiology and biotechnology
Alzheimer's disease (AD) is characterized by the presence of neurofibrillary tangles of hyperphosphorylated, aggregated tau protein and extracellular deposits of β‐amyloid peptide. Increased β‐amyloid levels are thought to precede tangle formation, but tau pathology is more closely related to neuronal death. Minocycline, a tetracycline derivative, has potent antiinflammatory, antiapoptotic, and neuroprotective effects in several models of neurodegenerative disease, including models of AD with amyloid pathology. We have used both in vitro and in vivo models of AD to determine whether minocycline may have therapeutic efficacy against tau pathology. In primary cortical neurons, minocycline prevents β‐amyloid‐induced neuronal death, reduces caspase‐3 activation, and lowers generation of caspase‐3‐cleaved tau fragments. Treatment of tangle‐forming transgenic mice (htau line) with minocycline results in reduced levels of tau phosphorylation and insoluble tau aggregates. The in vivo effects of minocycline are also associated with reduced caspase‐3 activation and lowered tau cleavage by caspase‐3. In tau mice, we find that conformational changes in tau are susceptible to minocycline treatment, but are not directly associated with the amount of tau fragments produced, highlighting a dissociation between the development of these pathological tau species. These results suggest a possible novel therapeutic role for minocycline in the treatment of AD and related tauopathies.— Noble, W., Garwood, C., Stephenson, J., Kinsey, A. M., Hanger, D. P., Anderton, B. H. Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. FASEB J. 23, 739–750 (2009)